NB Aurora’s Post

📢 Quercus and Augebit have taken up over 10% of the shares of BioResearch Pharma SA. Quercus Multistrategy FIZ, Augebit FIZ, the Manawa Family Foundation, and a group of managers affiliated with the company took part in the private placement of Series D shares. 🔹 BRP raised proceeds of over PLN 9 million. 🔹 The proceeds will be devoted to carrying out further research on BRP therapies which ultimately may be used to treat millions of people around the world suffering from androgenetic alopecia (project BRP-011) and plaque psoriasis (project BRP-007). More information in PAP Biznes/ Stooq.pl article: https://lnkd.in/dQW7seF3 #biotech #pharma #healthcare

#ONC (Mrkcap £8m at 11p/share) Turnarounds are difficult even at the best of times. Hence its vital that the leadership team is experienced, capable and hungry - because invariably there will be challenges and tough decisions to make. To me leading autoantibody profiling firm Oncimmune fits the bill. Indeed since taking the helm only 12 months ago, CEO Martin Gouldstone has refocused the business, slimmed down the cost base, and crucially re-energised the sales team - securing a series of contract wins with big pharma to help them discover, test & further improve their drugs Today came more positive news, with the company saying that it had signed a $1.5m (£1.16m) deal with an existing top 10 group. In fact after successfully completing a “breakthrough” pilot - using its high throughput bead based platform in order accurately profile Immunoglobulin E (IgE) autoantibodies in blood serum. This new contract is one of ImmunoINSIGHTS’ largest ever – demonstrating its ability to secure significant follow on work. The agreement is scheduled to be completed over next 6 months, with the majority of the revenue helping to underpin Cavendish’s (house broker) August FY25 sales target of £6.9m. In terms of FY24 trading, the Board reiterated its revenue guidance of £3m (vs £1.2m H1’24 and £1.15m LY) and is aiming to become profitable (Cavendish £0.8m adjusted PBT vs -£3.2m FY24) in FY25. Better still, given the turnaround is taking shape nicely - the next task is to reprofile its capital base. Here, #ONC has commenced discussions with IPF Management about amending the terms of its €6m credit facility, with the goal of deferring repayments to enable greater organic investment. At 11p, the stocks trades on modest multiples of 1.7x FY25 EV/sales and 7.7x EV/EBITDA. Whilst Cavendish have a target price of 50p/share. CEO Martin Gouldstone commenting: “I am delighted that our world-leading scientific team has managed to demonstrate our ability to measure IgE, which is much harder to detect in blood serum than other immunoglobulins, using our high-throughput platform. Not only did this enable us to win a major new contract with an existing long-term Top 10 Pharma customer, it also opens a new technological offering, in line with our strategic goals." "We are confident that, with this win and continued momentum of contracts, we are in a strong position to meet our targets for FY24 and beyond, with profitability expected in FY25." Disclosure: Oncimmune is a Vox Markets client.

Shield Therapeutics plc (AIM:STX, OTCQX:SHIEF) interim CEO Anders Lundstrom and CFO Santosh Shanbhag take Proactive's Stephen Gunnion through the company's impressive growth in the iron deficiency market. They discussed the key highlights from the first half of the year, including a 3.5x increase in Accrufer revenues, bringing in $11 million in total net revenue. Shanbhag emphasised this growth was driven by both increased prescriptions and improved pricing strategies. Lundstrom provided insights into Shield Therapeutics' broader market strategy, focusing on their collaboration with Viatris and global partners to expand Accrufer's reach. He highlighted recent milestones such as Health Canada's approval of Accrufer, marking a significant step in the company's global expansion. Shanbhag further detailed Shield's financial positioning, including maintaining $8.1 million in cash and strategic financing moves to support... Watch at #Proactive #ProactiveInvestors http://ow.ly/Re8U105HBFB

Shield Therapeutics plc CEO Anders Lundstrom and CFO Santosh Shanbhag joined Steve Darling from Proactice to share its released an unaudited Q3 2024 trading update revealing $7.2 million in net revenues from ACCRUFeR prescriptions, with an average net selling price of $167 per prescription. Excluding July's summer buying trends, the NSP averaged $192 in Q3, and Shield anticipates maintaining this level into Q4. Shield looks to gain traction, especially in the United States, where it partners with Viatris, deploying a sales force of 100 to promote ACCRUFeR. To support its objective of achieving cash flow positivity by 2025, Shield has expanded its working capital financing with Sallyport Commercial Finance from $10 million to $15 million. Additionally, Shanbhag also noted that steps are being taken to improve Shield’s cash position, including a planned 10% cost reduction and expanded financing from Sallyport, which he... Watch at #Proactive #ProactiveInvestors http://ow.ly/KFbx105Nh15

01/10/2024 🚨News alert 🚨 Mankind Pharma to Raise ₹1 tn Via NCDs, CPS Capital Raise: Mankind Pharma plans to raise up to ₹1 tn through non-convertible debentures (NCDs) and commercial papers (CPs). Board Approval: The company’s board has approved a total of ₹2.5 tn in NCDs, to be issued in 3-4 series with maturities of up to 48 months. Commercial Papers: An additional ₹500 bn will be raised via listed and rated commercial papers in one or more tranches. Acquisition Financing: This fundraising effort is part of Mankind Pharma's strategy to finance its acquisition of Bharat Serums and Vaccines for approximately ₹1.363 tn. Overall Fundraising Plan: Earlier reports indicated Mankind Pharma may seek to raise over ₹2.9 tn through a combination of NCDs and CPs. Conclusion: Mankind Pharma’s significant fundraising initiative underscores its commitment to strategic acquisitions and growth, positioning itself for future expansion in the pharmaceutical sector. Nifty cmp: ₹25835 Mankind pharma cmp: ₹2523 Under the guidance of Rishabh Kale sir

#ONC Executing successful corporate turnarounds is notoriously tricky - often costing more and taking longer than originally anticipated. However there are exceptions. Oncimmune being one, having hit all its key milestones in double quick time, since the new management team under CEO Martin Gouldstone took the helm in Aug’23. Indeed trading at this niche life sciences firm – that provides proprietary autoantibody profiling services to the drug development industry – continues to go from strength to strength. Its cutting edge ImmunoINSIGHTS platform has secured a slew of new orders. Which not only more than doubled revenues in year 1, but is also on track to repeat the feat in Aug FY25. The latest 3 contracts being signed with top 10 global pharmaceutical groups, covering new therapeutic areas &/or hard to profile autoantibodies (eg Immunoglobulin type E, IgE). The latter being a technological breakthrough for #ONC and the wider industry, underscoring the firm’s scientific expertise. All told, 8 contracts worth £2.14m have been signed over the last 3 months alone. Sure FY25 guidance might not have been upgraded. Yet this is simply because its still early in FY25 - whilst the improved visibility further underpins Cavendish’s (house broker) turnover and adjusted EBTDA targets of £6.9m (>40% revenue cover already) & £0.7m respectively. The former being >140% higher than Est FY’24 revenues of £2.8 LY, which itself is another 140% above FY’23 levels (£1.15m). This impressive progress hasn’t been lost on capital providers either. You see last month, the group raised £2.3m (gross) in a placing at 15p, alongside converting €4m of its €6m IPF debt into equity at 15p. Meaning now #ONC has the fire-power to accelerate its growth trajectory and become cashflow positive over the next 12 months.  So where are we now? Well as at Aug’24, ONC had a £3.2m sales pipeline of which 72% related to new clients. Plus “in the medium term, Oncimmune aspires to grow revenues to more than £20m by 2029”. Finally wrt valuation at 15p (£15.6m Mrkcap),the stock trades on a modest EV/sales multiple of 2.6x. Cavendish have a target price of 50p/share. CEO Martin Gouldstone commenting: “Following the fundraise, and successful debt recapitalisation of the business announced on the 18 Oct’24, I am pleased to see that our relentless focus on the commercial side of the business continues to bear fruit. These new wins with existing Top 10 Pharma customers keeps us on track to be a profitable business in FY’25.” Momentum is building. Disclosure: Oncimmune is a Vox Markets client

This week, MWP Partners became substantial holders of Island Pharmaceuticals, alongside some biotech heavies (with significantly more scientific pedigree than our own) including Daniel Tillett, Jason Carroll, Bill Garner and Chris Ntoumenopoulos. The capital provided will ensure Island can fully fund its Phase 2a/b trial targeting Dengue Fever and fast track the acquisition of Galidesivir, which primarily targets Ebola. What attracted us to this opportunity: - Large (and growing) market opportunity with Dengue infecting an estimate 400m people annually and no current treatment. - Dengue is becoming a ‘rich country’ problem with global warming expanding carrying mosquitos beyond equatorial regions into Southern America, Southern Europe and Northern Australia. - ILA-101 is a small molecule with clinical history. Having previously been developed by J&J for oncology, it has high safety profile and is well tolerated based on 45 human studies. Animal and cell studies, which for antivirals has great translation into humans, further show ILA-101 prevents viral replication and deaths from lethal Dengue. - The US Army, who are a natural stockpiler of an approved drug, is providing no-dilutive funding and cooperating with its R&D library to provide diluted strains of the virus for Island’s Phase 2 trial. - Dengue is the tip of the iceberg, with many other mosquito-borne disease targets including Zika, West Nile and Yellow Fever. - Island could be eligibile to receive Priority Review Voucher(s) following FDA approval for both ILA-101 and Galidesivir, which can be sold to big pharma for >US$100m a piece, providing substantial dilution-free funding. - Galidesivir has a potentially rapid pathway to market under the FDA’s ‘Animal Rule’, requiring only animal trials given the obvious unethical and safety concerns putting Ebola into humans. The market is beginning to recognise Island's potential and is off to a strong start as we await first readout of the Phase 2a results in November. Follow the journey and hope we put a dent in these crippling viruses. https://lnkd.in/g7-9hDDB

AstraZeneca's acquisition of French biotech Amolyt Pharma for 1 billion dollars marks a historic deal 🚀 AstraZeneca's recent acquisition of the French biotech company Amolyt Pharma for 1 billion dollars marks a significant move for the french biotech and for the pharmaceutical giant. This acquisition will enable AstraZeneca to expand its portfolio in the field of rare diseases, particularly focusing on rare endocrine disorders. Amolyt Pharma has been dedicated to developing treatments for rare endocrine disorders. The company holds the license for a treatment targeting a rare thyroid disease known as hypoparathyroidism. This condition, affecting approximately 115,000 individuals in the United States and 107,000 in the European Union, predominantly impacts women. With this acquisition, AstraZeneca aims to leverage Amolyt Pharma's expertise and innovative treatments to address the unmet medical needs of patients with rare endocrine diseases. https://lnkd.in/eijrxkTg

New Post: PureTech made millions on Karuna acquisition. Here’s what it plans to return to shareholders. -On Monday, Bristol Myers Squibb completed its acquisition of Boston drug developer Karuna Therapeutics Inc. for $14 billion. Karuna is a spinout of Boston-based PureTech Health, which will receive hundreds of millions of dollars from its stake in Karuna. Here’s what it plans to do withe the proceeds. Source link On Monday, Bristol Myers Squibb completed its acquisition of Boston drug developer Karuna Therapeutics Inc. for $14 billion. Karuna is a spinout of Boston-based PureTech Health, which will receive hundreds of millions of dollars from its stake in Karuna. Here's what it plans to do withe the proceeds. Source link